Glioma and the gut–brain axis: opportunities and future perspectives

Dono, Antonio; Nickles, Jack; Rodriguez-Armendariz, Ana G; McFarland, Braden C.; Ajami, Nadim J.; Ballester, Leomar Y.; Wargo, Jennifer A.; Esquenazi, Yoshua

doi:10.1093/noajnl/vdac054

Cited by 20 publications

(14 citation statements)

References 77 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The gut microbiota and metabolome have been reported to play key roles in the regulation of several processes related to brain functions [ 18 , 52 , 53 ] and host disease pathogenesis [ 54 , 55 ]. Dysbiosis in the gut can be caused by several factors such as imbalanced diets, infections, environmental stressors and use of drugs, all affecting gut microbial diversity and establishing the conditions for host susceptibility to diseases [ 56 ].…”

Section: Discussionmentioning

confidence: 99%

Antibiotics treatment promotes vasculogenesis in the brain of glioma-bearing mice

Rosito,

Maqbool,

Reccagni

et al. 2024

Cell Death Dis

View full text Add to dashboard Cite

In recent years, several studies described the close relationship between the composition of gut microbiota and brain functions, highlighting the importance of gut-derived metabolites in mediating neuronal and glial cells cross-talk in physiological and pathological condition. Gut dysbiosis may affects cerebral tumors growth and progression, but the specific metabolites involved in this modulation have not been identified yet. Using a syngeneic mouse model of glioma, we have investigated the role of dysbiosis induced by the administration of non-absorbable antibiotics on mouse metabolome and on tumor microenvironment. We report that antibiotics treatment induced: (1) alteration of the gut and brain metabolome profiles; (2) modeling of tumor microenvironment toward a pro-angiogenic phenotype in which microglia and glioma cells are actively involved; (3) increased glioma stemness; (4) trans-differentiation of glioma cells into endothelial precursor cells, thus increasing vasculogenesis. We propose glycine as a metabolite that, in ABX-induced dysbiosis, shapes brain microenvironment and contributes to glioma growth and progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibiotics treatment promotes vasculogenesis in the brain of glioma-bearing mice

Rosito,

Maqbool,

Reccagni

et al. 2024

Cell Death Dis

View full text Add to dashboard Cite

show abstract

“…As described, gut microbiota-derived metabolites contribute to the pathogenesis of neurodegenerative diseases via disruption of blood-brain barrier integrity, affecting brain functions ( 117 ). The emerging evidence of the role of the gut-brain axis in neuro-oncology has been recently reviewed ( 118 ). Patrizz et al.…”

Section: The Study Of Tumor Microbiome In Various Solid Malignanciesmentioning

confidence: 99%

Tumor microbiome – an integral part of the tumor microenvironment

et al. 2022

View full text Add to dashboard Cite

The tumor microenvironment (TME) plays a significant role in tumor progression and cancer cell survival. Besides malignant cells and non-malignant components, including immune cells, elements of the extracellular matrix, stromal cells, and endothelial cells, the tumor microbiome is considered to be an integral part of the TME. Mounting evidence from preclinical and clinical studies evaluated the presence of tumor type-specific intratumoral bacteria. Differences in microbiome composition between cancerous tissues and benign controls suggest the importance of the microbiome-based approach. Complex host-microbiota crosstalk within the TME affects tumor cell biology via the regulation of oncogenic pathways, immune response modulation, and interaction with microbiota-derived metabolites. Significantly, the involvement of tumor-associated microbiota in cancer drug metabolism highlights the therapeutic implications. This review aims to summarize current knowledge about the emerging role of tumor microbiome in various types of solid malignancies. The clinical utility of tumor microbiome in cancer progression and treatment is also discussed. Moreover, we provide an overview of clinical trials evaluating the role of tumor microbiome in cancer patients. The research focusing on the communication between the gut and tumor microbiomes may bring new opportunities for targeting the microbiome to increase the efficacy of cancer treatment and improve patient outcomes.

show abstract

“…In addition, mutations in Y727C and E840K of PDE11A have been reported to be extremely high expressed in prostate cancer ( 90 ). Moreover, the role of PDE11A in brain tumors has recently been studied and reported due to the brain belongs to an essential part of the human body and is responsible for a critical part of the CNS ( 91 ). All brain cancers are graded from 1 to 4 based on how the cancer cells look under the microscope and how well they reproduce.…”

Section: Pde11a and Tumorsmentioning

confidence: 99%

Functional characteristics and research trends of PDE11A in human diseases (Review)

Kong

Lee

et al. 2022

Mol Med Rep

View full text Add to dashboard Cite

caMP and cGMP are important secondary messengers involved in cell regulation and metabolism driven by the G protein-coupled receptor. caMP is converted via adenylyl cyclase (ac) and activates protein kinase a to phosphorylate intracellular proteins that mediate specific responses. cAMP signaling serves a role at multiple steps in tumorigenesis. The level of caMP is increased in association with cancer cell formation through activation of ac-stimulatory G protein by mutation. Phosphodiesterases (Pdes) hydrolyze caMP and cGMP to aMP and GMP. Pdes are composed of 11 families, and each can hydrolyze caMP and cGMP or both caMP and cGMP. Pdes perform various roles depending on their location and expression site, and are involved in several diseases, including male erectile dysfunction, pulmonary hypertension, alzheimer's disease and schizophrenia. Pde11a is the 11th member of the Pde family and is characterized by four splice variants with varying tissue expression and n-terminal regulatory regions. among tissues, the expression of Pde11a was highest in the prostate, and it was also expressed in hepatic skeletal muscle, pituitary, pancreas and kidney. Pde11a is the first PDE associated with an adrenocortical tumor associated genetic condition. in several studies, three Pde11a mutations have been reported in patients with cushing syndrome with primary pigmented nodular adrenocortical disease or isolated micronodular adrenocortical disease without other genetic defects. it has been reported that an increase in Pde11a expression affects the proliferation of glioblastoma and worsens patient prognosis. The present mini-review summarizes the location of Pde11a expression, the impact of structural differences and disease relevance. Contents1. introduction 2. caMP/cGMP-dependent signaling 3. Phosphodiesterase family 4. Pde11a and tumors 5. other diseases cause by Pde11a 6. Further focus for Pde11a

show abstract

Glioma and the gut–brain axis: opportunities and future perspectives

Cited by 20 publications

References 77 publications

Antibiotics treatment promotes vasculogenesis in the brain of glioma-bearing mice

Antibiotics treatment promotes vasculogenesis in the brain of glioma-bearing mice

Tumor microbiome – an integral part of the tumor microenvironment

Functional characteristics and research trends of PDE11A in human diseases (Review)

Contact Info

Product

Resources

About